全文获取类型
收费全文 | 154619篇 |
免费 | 31379篇 |
国内免费 | 2434篇 |
专业分类
耳鼻咽喉 | 5214篇 |
儿科学 | 5419篇 |
妇产科学 | 2417篇 |
基础医学 | 3548篇 |
口腔科学 | 1588篇 |
临床医学 | 26790篇 |
内科学 | 48246篇 |
皮肤病学 | 7495篇 |
神经病学 | 15085篇 |
特种医学 | 6463篇 |
外科学 | 41805篇 |
综合类 | 247篇 |
现状与发展 | 72篇 |
一般理论 | 1篇 |
预防医学 | 7014篇 |
眼科学 | 3404篇 |
药学 | 1170篇 |
中国医学 | 11篇 |
肿瘤学 | 12443篇 |
出版年
2024年 | 685篇 |
2023年 | 4796篇 |
2022年 | 1218篇 |
2021年 | 3135篇 |
2020年 | 6049篇 |
2019年 | 2190篇 |
2018年 | 7448篇 |
2017年 | 7389篇 |
2016年 | 8496篇 |
2015年 | 8489篇 |
2014年 | 15607篇 |
2013年 | 15735篇 |
2012年 | 5653篇 |
2011年 | 5727篇 |
2010年 | 10488篇 |
2009年 | 14344篇 |
2008年 | 6009篇 |
2007年 | 4249篇 |
2006年 | 6712篇 |
2005年 | 4000篇 |
2004年 | 3272篇 |
2003年 | 2243篇 |
2002年 | 2322篇 |
2001年 | 3860篇 |
2000年 | 3061篇 |
1999年 | 3285篇 |
1998年 | 3713篇 |
1997年 | 3535篇 |
1996年 | 3405篇 |
1995年 | 3252篇 |
1994年 | 1997篇 |
1993年 | 1608篇 |
1992年 | 1428篇 |
1991年 | 1447篇 |
1990年 | 1082篇 |
1989年 | 1207篇 |
1988年 | 1049篇 |
1987年 | 881篇 |
1986年 | 915篇 |
1985年 | 732篇 |
1984年 | 568篇 |
1983年 | 531篇 |
1982年 | 526篇 |
1981年 | 409篇 |
1980年 | 367篇 |
1979年 | 314篇 |
1978年 | 340篇 |
1977年 | 405篇 |
1975年 | 285篇 |
1972年 | 304篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
4.
6.
7.
8.
9.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
10.